Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -1.320% | 5.152% | 3.274% | 0.434% | -26.092% | -33.355% | -28.796% |
| Opko Health Inc. | 3.330% | 11.321% | 31.111% | 0.648% | 8.237% | -9.523% | -60.875% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -0.600% | 0.000% | -5.618% | -13.402% | -14.286% | -42.069% | -31.148% |
Comments
News
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
Key Points
- Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better.
- BeOne Medicines used its ASCO investor update to signal a major push beyond hematology
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026